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for prostate cancer—a new dawn for an old therapy
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INTRODUCTION—A HISTORICAL 
PERSPECTIVE
In 1941, Huggins and Hodges published the first 
description of a clinical response to estrogen 
therapy in patients with advanced carcinoma of 
the prostate (CaP).1 Over the next four decades, 
estrogens (and orchiectomy) were the primary 
management for all patients with CaP, their unfet-
tered use propagated by two large pooled, but 
retrospective analyses concluding that estrogens 
improved survival for all stages of the disease.2,3 
The recognition of the hormonal influences on 
CaP and the potential to manipulate the natural 
history of the disease by androgen suppression led 
to Charles Huggins being awarded the Nobel Prize 
in 1966, thereby becoming the only urologist ever 
to receive such an honor. 
It was not until the publication of the 
first controlled studies by The Veterans 
Administration Cooperative Urological Research 
Group (VACURG) that the discrepancy between 
disease-specific survival and overall survival 
was recognized.4–6 In these studies, estrogen 
therapy achieved clinical responses in up to 
80% of patients, and delayed disease progres-
sion; however, there was little evidence that any 
type of hormone manipulation improved overall 
survival. These studies also revealed a signifi-
cantly increased risk of cardiovascular toxicity in 
up to 35% of patients receiving estrogen therapy; 
thromboembolism was experienced by 15%. 
The VACURG studies concluded that estrogen 
therapy should be reserved for those with 
advanced and symptomatic disease.6 Following 
the development of luteinizing hormone-
releasing hormone (LHRH) agonists and subse-
quently nonsteroidal anti-androgens (NSAAs) 
with equivalent oncological effect and lesser 
cardiovascular toxicity, the use of and research 
into estrogen therapy rapidly declined. 
Contemporary first-line androgen suppres-
sion therapy worldwide is based on the use of 
LHRH agonists, NSAAs or orchiectomy. Whilst 
these treatments have a lower incidence of cardio-
vascular toxicity compared with oral estrogen, 
Oral estrogens were the treatment of choice for carcinoma of the 
prostate for over four decades, but were abandoned because of an excess 
of cardiovascular and thromboembolic toxicity. It is now recognized 
that most of this toxicity is related to the first pass portal circulation, 
which upregulates the hepatic metabolism of hormones, lipids and 
coagulation proteins. Most of this toxicity can be avoided by parenteral 
(intramuscular or transdermal) estrogen administration, which avoids 
hepatic enzyme induction. It also seems that a short-term but modest 
increase in cardiovascular morbidity (but not mortality) is compensated 
for by a long-term cardioprotective benefit, which accrues progressively 
as vascular remodeling develops over time. Parenteral estrogen therapy 
has the advantage of giving protection against the effects of andropause 
(similar to the female menopause), which are induced by conventional 
androgen suppression and include osteoporotic fracture, hot flashes, 
asthenia and cognitive dysfunction. In addition, parenteral estrogen 
therapy is significantly cheaper than contemporary endocrine therapy, 
with substantive economic implications for health providers.
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Data for this review were identified by searching the PubMed and MEDLINE 
databases. The search terms used alone or in combination were “prostate 
cancer”, “estrogen”, “estradiol”, “treatment”, “prognosis”, “administration route”, 
“transdermal administration”, “cutaneous administration”, “administration 
and dosage”, “toxicity”, “side effects”, “adverse effects”, “complications”, 
“thromboembolism”, “fibrinolysis”, “blood coagulation factors”, “blood vessels”, 
“blood flow velocity”, “bone metastases”, “osteoporosis”, “bone fracture”, “hot 
flashes”, “castration”, “andropause”, and “quality of life”. The search was limited to 
articles published in English and indexed up until December 2005.
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they are still associated with significant morbidity. 
Hypogonadism, as a result of androgen suppres-
sion therapy, causes accelerated osteoporosis and 
a significant increase in the risk of osteoporotic 
fracture.7,8 Androgen suppression therapy 
also induces an andropausal state (castration 
syndrome) characterized by hot flushes, loss 
of libido, reduced energy levels and cognitive 
dysfunction.9,10 As evidence accumulates that 
initiation of androgen suppression during early-
stage disease may improve outcome,11–13 there 
is increasing concern that long-term androgen 
deprivation may paradoxically be the cause of 
complications that it was hoped to avoid. By 
contrast, estrogen therapy in the form of hormone 
replacement therapy (HRT) is an established 
treatment for the equivalent condition (meno-
pause) in women.14 An estrogenic formulation 
with similar oncological benefits to oral estrogen 
and the advantages inherent to the estrogenic 
milieu, but with reduced cardio vascular toxicity, 
would therefore appear an attractive proposition 
in the treatment of CaP.
MECHANISMS OF ESTROGEN TOXICITY
Toxicity (and clinical response) is related 
to dose
The accepted dose of oral estrogen, 3 mg diethyl-
stilbestrol (DES), was based on historical studies 
to establish equivalence to castrate levels of 
testosterone.15 This dose was established as the 
‘standard’ even though the VACURG studies 
demonstrated that a lower 1 mg dose of DES had 
equivalent oncological effect, as well as a reduced 
cardiovascular toxicity.5 The non-cancer-related 
mortality rate in the 3 mg (and 5 mg) DES arms of 
the VACURG studies was 29.6%, compared with 
21.6% for the non-estrogen treatments (relative 
risk of estrogen-related mortality 1.45). Almost 
all of this difference in mortality was due to an 
excess of cardiovascular mortality (17.0% versus 
11.7%) for the higher dose estrogen arms, mani-
fest within the first months after treatment was 
initiated. By contrast, the 1 mg dose of DES was 
associated with a significantly lower level of cardio-
vascular toxicity; the overall non-cancer-related 
mortality was 21%, similar to that observed in 
the non-estrogen arms.5 Subsequent studies have 
established that the risk of serious cardio vascular 
morbidity with a 3 mg dose of DES ranges 
between 30 and 35%.16–19 
In 1995, the European Organisation for Research 
and Treatment of Cancer (EORTC) published its 
study comparing orchiectomy, orchiectomy plus 
cyproterone acetate (which causes maximum 
androgen blockade; MAB), and low-dose 1 mg 
DES in patients with metastatic disease.20 This 
study provided the first opportunity to evaluate 
the efficacy and toxicity of low-dose DES since the 
publication of the VACURG studies. No differences 
were seen in time to progression or overall survival 
between the three treatment arms; however, the 
cardiovascular toxicity and mortality rate (14.8%) 
with the 1 mg dose of DES approached twice 
that with orchiectomy alone (8.3%). This differ-
ence was most marked in patients with a prior 
history of cardiovascular disease. In a smaller, 
single- institution study, 106 patients with 
advanced CaP were initially treated with a 1 mg 
daily dose of DES, which was subsequently titrated 
depending on hormonal and prostate-specific 
antigen (PSA) responses.21 Although only 27% of 
the patients achieved castrate levels of testosterone 
with 1 mg DES, 66% achieved a sustained PSA 
response. A secondary response occurred in 33% 
of the patients with biochemical (PSA) failure 
once the DES dose was doubled. Cardiovascular 
toxicity was noted in 7.5% of patients, but only 
one life-threatening (thromboembolic) event 
occurred. Bishop and co-workers21 suggested 
that low-dose estrogen titrated to levels that 
produced hormonal and clinical responses could 
achieve efficacy with acceptable toxicity levels. It 
is evident, however, that the cardiovascular risk 
encountered with oral estrogen therapy, even 
at low doses, compares unfavorably to rates of 
3–6% cardiovascular mortality, and 8–20% cardio-
vascular morbidity expected during treatment 
with orchiectomy or LHRH agonists.22 As such, 
dose modulation for oral estrogen therapy has not 
been pursued.
The relationship between dose response and 
cardiovascular toxicity for parenteral estrogen 
therapy is less well defined. The dose of intra-
muscular estrogen depot, polyestradiol phos-
phate (PEP), utilized in Scandinavia as first-line 
hormone therapy, was established by a sequence 
of pilot studies that compared four doses (80 mg, 
160 mg, 240 mg and 320 mg) and different depot 
scheduling (induction and maintenance regimes) 
to achieve rapid castration and thereafter maintain 
castrate levels of testosterone.23–25 The patient 
numbers in these pilot studies were small (Table 1) 
and the methodologies simplistic—although 
the dosing regimens were predicted using statis-
tical computer modeling, the dose adjustments 
were based on retrospective testosterone assay, 
rather than, ideally, prospective dose-response 
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pharmaco kinetic profiling. Nevertheless, the dose 
and schedule established (and utilized in larger 
studies) achieved castrate levels of testosterone 
in all patients and are, therefore, presumed to 
be bioequivalent to the 3 mg dose of oral DES. 
Cardiovascular toxicity was not observed in these 
pilot studies.23–25 In the single pilot study of 
transdermal estradiol,26 dose was also titrated to 
Table 1 Studies using parenteral estrogens for the treatment of men with advanced prostate cancer.
Study and reference Study type Patient 
number
Median 
follow-up 
(months)
Cardiovascular risk 
and complications 
Finnprostate studies
PEP versus orchidectomy
Haapiainen et al. (1990)69
Comparative 200 24 Mortality 1.6% PEP versus 1.3% 
orchiectomy (morbidity not reported)
PEP versus orchidectomy 
Aro (1991)44
Epidemiological 477 72 Relative cardiovascular risk 0.17 
PEP versus 0.78 orchiectomy 
PEP versus LHRH agonist 
Aro et al. (1993)70
Comparative 147 36 Morbidity 7.1% PEP versus 7.8% 
LHRH agonist
Mortality 5.7% PEP versus 5.2% 
LHRH agonist
PEP versus LHRH agonist 
Lukkarinen and Kontturi 
(1994)71
Comparative 236 23 Morbidity 19.6% PEP versus 9.3% 
LHRH agonist
Mortality 6.5% PEP versus 6.2% 
LHRH agonist
PEP versus orchidectomy 
Mikkola et al. (1998)36; 
(2005)43
Randomized 444 24 Overall morbidity 6.0% PEP versus 
1.4% orchiectomy, first year
Overall morbidity 6% PEP versus 
4% orchiectomy, second year 
(difference not significant)
T3–4 M0 years 1–3 PEP (4.8%, 
6.3%, 6.7%) versus orchiectomy 
(0.8%, 2.7%, 1.9%)
T1–4 M1 years 1–3 PEP (8.8%, 
4.7%, 0%) versus orchiectomy 
(2.0%, 6.3%, 2.9%)
SPCG studies
PEP
Henriksson et al. (1988)23
Pilot 38 14.1 0%
PEP
Stege et al. (1988)24
Pilot 27 6 0%
PEP
Stege et al. (1989)25
Pilot 17 12 0%
Oral, PEP and orchidectomy 
Carlstrom et al. (1989)27
Pilot 48 12 0%
PEP versus orchidectomy
Henriksson et al. (1999)45
Randomized 33 24 6% PEP versus 24% orchidectomy
(statistical analysis not provided)
PEP versus MAB
Hedlund and Henriksson 
(2000)35; Hedlund et al. 
(2002)46
Randomized 917 18.5 Overall mortality 16% PEP versus 
14% MAB (difference not significant)
Cardiovascular mortality 3.5% PEP 
versus 3.1% MAB (difference 
not significant)
Cardiovascular morbidity 12.5% 
PEP versus 7.9% MAB
Other studies
PEP versus orchidectomy 
Bishop et al. (1989)21
Comparative 117 Not 
recorded
Morbidity 13.1% PEP versus 7.1% 
orchiectomy
Transdermal estradiol 
Ockrim et al. (2003)26
Pilot 20 12 Morbidity 5%
LHRH, luteinizing hormone-releasing hormone; MAB, maximum androgen blockade; PEP, polyestradiol phosphate; SPCG, Scandinavian 
Prostate Cancer Group
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castrate testosterone (due to clinical necessity in 
symptomatic patients). Rapid induction using six 
patches per week of 7.8 mg Progynova® TS forte 
(Schering Aktiengesellschaft Berlin, Germany) 
was used for symptomatic disease control before 
the dose was titrated downwards according to the 
predicted pharmacokinetic requirements and 
the testosterone assays. Dose modulation was 
easily achieved by using between two and 
three patches per week (washout occurs within 
24 hours) according to monthly testosterone 
levels. As such, the serum estradiol levels achieved 
(Figure 1) are also assumed to be equivalent to a 
3 mg DES dose. Whilst bioequivalence between 
oral and parenteral estrogen administration is still 
not completely resolved (and pharmaco kinetic 
work is still required), the parenteral doses of 
estrogen in use have equivalent oncological effect 
to other hormone therapies and can be taken 
as valid clinical comparators when evaluating 
relative toxicities.
Toxicity is related to route of administration
Much of the adverse cardiovascular toxicity of 
oral estrogen therapy is now recognized to be 
related to the route of administration. The direct 
exposure of the liver to high doses of estrogen, via 
the portal circulation, upregulates the metabolism 
of hormones, lipids and coagulation proteins, all 
contributing to the changes thought to be respon-
sible for short-term and long-term cardiovascular 
events.26–29 Avoidance of enteric absorption 
using parenteral routes of administration (intra-
venous, intramuscular and transdermal) signifi-
cantly reduces this metabolic upregulation. While 
oral estrogens cause multi-fold increases in the 
ratio of estradiol and its metabolites (particularly 
estrone), the physiological ratios of sex hormones 
and their binding globulins are not affected by 
equivalent doses of parenteral estrogen.26,27 
Similarily, the physiological ratios of HDLs and 
LDLs and other lipids are reversed with oral 
estrogens, but the cardioprotective ratios are 
preserved with parenteral estrogen administra-
tion.30 Clinically, the most apparent adverse effect 
of oral estrogens is venous and arterial thrombo-
embolism, which is manifest as transient ischemic 
attack, cerebrovascular accident and myocardial 
infarction. These thromboembolic events are 
associated with a marked increase in activated 
coagulation proteins (including factors VII, VIII, 
IX, and X and fibrinogen), decreases in inhibitors 
of coagulation (antithrombin III, protein S and 
tissue factor pathway inhibitor) and increased 
levels of fibrinolytic factors (plasminogen, tissue 
plasminogen activator and D-dimer).29 
Parenteral estrogens do not cause such 
changes, and have been shown to reduce the 
levels of thrombo philic activation, particularly 
prothrombin fragments F1 and F2, fibrinogen and 
D-dimer, which are often associated with advanced 
CaP (Figure 2).31 The thrombophilic data seem to 
be well supported by the clinical studies (discussed 
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Figure 1 Pituitary–testicular response to transdermal estradiol therapy and the 
PSA response (mean and standard error mean) over 12 months. Abbreviations: 
FSH, follicle-stimulating hormone; LH, luteinizing hormone; PSA, prostate-
specific antigen. Permission obtained from Lippincott, Williams & Wilkins © 
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below), but also by studies of patients undergoing 
gender reassignment, in whom a 20-fold increase 
in the incidence of thromboembolism was 
negated by conversion from oral to transdermal 
estradiol preparations.32
Toxicity is related to changes in vascular 
flow over time
The other major determinant of estrogen toxicity 
appears to be related to the vascular changes 
incurred on the arterial circulation over time. 
Estrogens initially cause arterial dilatation (but 
less venous effect) and an associated reduction 
in arterial compliance (stiff arteries). In addition, 
cardiac demands and capillary filtration increase, 
resulting in an increased incidence of peripheral 
and pulmonary edema and cardiac decompen-
sation.33,34 It is now apparent that this effect is 
time-dependent, and most of this risk is mani-
fest within the first months (over 75% within 
the first 6 months) of estrogen therapy.17,35,36 
Over time the arterial compliance improves 
(Figure 3), possibly as a result of estrogen-
driven vascular remodeling leading to improved 
cardiovascular dynamics.37,38 Time dependency 
may be explained by the dual mode of action 
that estrogen has on the vasculature.33,34,36–38 
Immediate changes in vascular compliance are 
mediated by the release of endothelial-derived 
vasodilatory factors (endothelium- dependent 
vasodilatation). Long-term modulation of 
vascular compliance is a consequence of vascular 
wall remodeling, a gradual response to estrogen-
stimulated transcriptional (genomic) activation. 
The cardiovascular benefit only emerges once 
the vascular adaptation is sufficient to reduce the 
overall cardiac workload.37,38 
The time-dependent aspect of the cardio-
protective effect of HRT has only recently 
been recognized in postmenopausal women. 
Epidemiological studies have repeatedly suggested 
a cardioprotective effect of estrogen, with an 
overall risk reduction of around 30–50%.14,39 
Until recently, it was assumed that this vascular 
benefit was immediate, but the results of the first 
prospective study of the Heart and Estrogen/
progestin Replacement Study (HERS) established 
otherwise.40 The HERS unexpectedly demon-
strated an increase in cardio vascular events in 
the first year. The favorable cardiovascular effect 
was not established until 2 years after treatment 
initiation; however, the cardioprotective benefit 
increased consistently for the 3 years thereafter. 
This time trend has also been supported by 
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data from the Nurses’ Health Study,41 in which 
patients initially excluded from analyses because 
of baseline coronary artery disease also showed 
a temporary increase in cardiovascular risk in 
the first year (relative risk 1.25), followed by a 
later decrease in cardiovascular toxicity such that 
long-term users, up to 20 years, had a signifi-
cant reduction in cardiac events (relative risk 
0.65). These data would suggest that parenteral 
estrogen therapy for CaP may be best reserved for 
patients with a predicted prognosis longer than 
2 years, where long-term cardiovascular protec-
tion would compensate for an early increase in 
the risk of cardiovascular morbidity. In addition, 
parenteral estrogen therapy seems suitable as a 
second-line hormone escape therapy, where an 
initially increased (but substantially lower than 
oral estrogen) risk of cardiovascular complica-
tion might be deemed more acceptable. Given 
the gradual dynamic of vascular remodeling, 
with the cardiovascular toxicity loaded ‘up front’, 
it is unlikely that parenteral estrogen will be 
judged acceptable for intermittent use. Vascular 
changes after estrogen treatment is withdrawn 
are unknown.
TOXICITY IN CLINICAL STUDIES 
OF PARENTERAL ESTROGEN
Are the findings discussed above supported by 
clinical data of parenteral estrogen treatment in 
men with CaP? To date, only 13 studies have been 
published on the use of parenteral estrogens in CaP 
(Table 1). The quality of the limited data available 
and particularly the problems of inclusion criteria, 
dose variability and outcome assessment, is the 
subject of a recent systematic review.42 Pooled 
data analysis proved impossible, but this review 
and historical comparisons of oral estrogen and 
LHRH agonists suggest that cancer-specific effi-
cacy is essentially equivalent between the two treat-
ments. Most of the data pertaining to toxicity come 
from the two Scandinavian groups who use intra-
muscular PEP to treat patients with CaP.35,36,43–46 
In the Finnprostate studies comparing PEP to 
orchiectomy there was an increased cardiovascular 
morbidity in the first 2 years of therapy (11% with 
PEP versus 5% with orchiectomy), although the 
disparity was only statistically significant within 
the first year.36 Data on the breakdown of cardio-
vascular toxicity over 3 years of PEP treatment 
were recently published.43 For patients with meta-
static disease, PEP-related cardiovascular toxicity 
(9%) was higher than orchiectomy-related cardio-
vascular toxicity(2%) in the first year, but not in 
the subsequent 2 years (PEP 5% at year 2 and 0% 
at year 3 versus orchiectomy 6% at year 2 and 3% at 
year 3). The cardiovascular toxicity for patients 
with locally advanced but nonmetastatic disease, 
however, remained consistently higher over three 
years of treatment for the PEP-treated patients 
(5%, 6%, and 7%) than for those treated by 
orchiectomy (1%, 3%, and 2%). The discrepancy 
between the two groups is not explained. Based on 
these (unique) data, the authors suggest that PEP 
should be avoided as a first-line therapy in locally 
advanced disease, but make no recommendation 
for treatment of metastatic patients. By contrast, 
a longitudinal risk analysis of 477 Finnprostate 
patients projected over 10 years suggested that the 
long-term cardiovascular trend was subsequently 
reversed; the relative cardiovascular risk was 
0 6
Month
P
I (
%
 c
ha
ng
e)
12
2.0–
1.5–
1.0–
0.5–
0–
0.5–
–1.0–
–1.5–
–2.0–
0 6
Month
A
rt
er
ia
l b
lo
od
 fl
ow
 m
l/1
00
 m
l/m
in
12
40–
30–
20–
10–
0–
–10–
–20–
–30–
–40–
Figure 3 Arterial blood and capillary filtration 
increase during transdermal estradiol therapy, 
a possible explanation for increased risk of 
edema and cardiac decompensation. The arterial 
compliance (an inverse of the pulsatility index, 
shown here) initially reduces, but improves over 
the second 6 months of therapy. This improvement 
explains the improved vascular dynamics 
and cardioprotective benefits that accrue 
subsequently. Abbreviation: PI, pulsatility index. 
Permission obtained from Blackwell Publishing 
© Ockrim JL et al. (2006) BJU Int 97: 498–504.
ncponc_2006_021.indd   557 13/9/06   2:57:39 pm
Nature Publishing Group ©2006
REVIEW
558  NATURE CLINICAL PRACTICE  ONCOLOGY    OCKRIM ET AL.   OCTOBER 2006  VOL 3  NO 10
www.nature.com/clinicalpractice/onc
calculated at 1.51 for those using oral estrogens, 
0.78 for those treated by orchiectomy and only 
0.17 for those using PEP.44 The Finnprostate find-
ings are supported by those of the Scandinavian 
Prostatic Cancer Group (SPCG) consisting of 
four pilot studies, which together contain over 
1,000 patients (Table 1).23,25,27,45 The SPCG-5 
study randomized 917 men to treatment with 
either PEP or MAB.35 The PEP cardiovascular 
morbidity was substantially reduced compared 
with that expected from the equivalent dose of 
oral estrogen (expected oral estrogen toxicity up to 
35.0% versus 12.5% for PEP and 7.9% for MAB). 
Notably, the PEP group had a higher prevalence 
of cardio vascular disease prior to study. The overall 
cardio vascular mortality was equivalent (3.5% PEP 
versus 3.1% MAB) after 27 months.35,46 Further 
analysis of the cardiovascular toxicity is pending. 
These results are encouraging, but clearly need 
further validation and longitudinal follow-up.
ADVANTAGES OF PARENTERAL 
ESTROGEN THERAPY
The traditional concerns of clinicians treating 
CaP have been disease-specific and overall 
survival. Following the findings of the VACURG 
studies,4–6 endocrine therapy was limited to those 
with advanced and mostly symptomatic disease, 
in which the palliative treatment effect was most 
marked and the anticipated length of therapy 
short. In this setting, the benefits of therapy more 
easily prevail over any long-term side effects. In 
recent times, the management protocols for CaP 
have become more complex. The earlier diag-
nosis of CaP caused by PSA screening, the greater 
number of available endocrine treatment options, 
and the increased expectations of effective therapy 
by patients, have all stimulated a renewed interest 
in the timing and nature of hormonal inter-
ventions. The best evidence at present suggests that 
early hormonal therapy may provide a survival 
benefit for CaP patients with nodal metastases or 
biochemical failure after radical prostatectomy 
(and as adjuvant to radical radiotherapy).11,13 
Equally important is the recognition that early 
hormonal therapy for these patients, and also 
patients with early asymptomatic (high-grade) 
metastatic disease, might delay progression and 
reduce both symptoms and complication rates.12 
On this basis, many urologists now offer androgen 
suppression therapy to patients much earlier in the 
natural history of the disease. Thus, the duration 
many patients are exposed to hormonal therapy 
has significantly increased,47 and consequently the 
disparity between palliative benefit and the accu-
mulation of toxicity has become less distinct. In 
settings in which long-duration endocrine therapy 
is anticipated, issues pertaining to the impact on 
overall quality of life (QOL), patients’ ability to 
function normally and treatment-related side 
effects have now become as important parameters 
as disease outcome. Parenteral estradiol therapy 
might offer significant QOL advantages over 
contemporary hormone therapies.
Parenteral estrogen therapy 
and osteoporosis
Bone loss from protracted androgen suppression 
is of increasing concern amongst urologists and 
the wider medical community. Contemporary 
hormone therapies are all associated with signifi-
cant reduction in bone mass, with reported 
reductions of between 2.4% and 10.0% during 
the first year of treatment, and further losses of 
between 1.4% and 2.6% observed annually for 
up to 10 years following initiation of androgen 
suppression therapy.7,8,48,49 These losses exceed 
those reported in untreated menopausal women, 
and are associated with high risk of osteoporotic 
fracture.50 The accumulated incidence of osteo-
porotic fracture after androgen suppression 
is 28% after 7 years and 40–50% after 9 years, 
compared with a 1% incidence for men with 
untreated CaP observed during the same time 
period.8 The overall fracture risk is increased 
by 3.5-fold for those using conventional 
hormone therapies.51 It is not surprising that 
such numbers have encouraged pharmaceutical 
companies to include adjuvant drug therapy 
to protect bone density during routine patient 
care. Bisphosphonate therapy (currently used as 
monthly intravenous infusions) adds a signifi-
cant burden to patients and a major additional 
cost to health providers. Whilst the role of oral 
bisphosphonate therapy has yet to be fully estab-
lished, intravenous therapy remains invasive and 
limited to those with the most severe disease.49 
By contrast, estrogens (HRT) have a long 
established role in osteoprotection for post- 
menopausal women. We have recently published 
preliminary evidence to demonstrate that osteo-
protection is also conferred to patients with 
advanced CaP treated with transdermal estra-
diol.52 Bone density in our series improved by 
1.9–3.6% at 1 year (Figure 4) and improved 
the classification of patients with bone densi-
ties in the ‘at risk’ range. These improvements 
in bone density have an inherent advantage to a 
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population already susceptible to significant 
skeletal morbidity (i.e. osteoporotic fracture).
Parenteral estrogen therapy and hot flashes 
Hot flashes are the most commonly reported side 
effect of conventional hormonal therapy, with up 
to 80% of men experiencing persistent flashes 
after orchiectomy, LHRH agonists or MAB.53,54 
Flashes severe enough for palliation are docu-
mented in one-third of patients and cause disa-
bling distress in over 10%.53,54 The incidence of 
flashes and severity of the symptoms caused by 
estrogen therapy are far less than that caused 
by conventional hormonal therapies. In the 
SPCG-5 study, distressing hot flashes were docu-
mented in 36.7% of patients treated by MAB but 
only 5.4% of those treated by intramuscular PEP. 
In addition, the flashes resolved in over half the 
PEP-treated patients after 1 year of therapy.54 
Transdermal estrogens induce complete or 
partial relief in up to 90% of patients with CaP 
who suffered symptomatic flashes after taking 
conventional hormone therapy.55 
Parenteral estrogen therapy 
and gynecomastia 
Gynecomastia is a well-recognized effect of oral 
and also parenteral estrogen therapy. The reported 
incidence (and severity) of this event varies from 
40% to 77%.19,20,35 In our study, transdermal 
estradiol caused mild discomfort in 63% of the 
patients and modest discomfort in the remaining 
37%.26 The distress was worst in the first 6 months 
of therapy; thereafter, the gynecomastia stabilized, 
and the distress decreased for most patients. These 
findings are consistent with the level of painful 
gynecomastia reported for 3 mg DES therapy.19 
Gynecomastia can be effectively prevented by 
the use of pretreatment radiotherapy given as a 
single or fractionated therapy. The side effects of 
this therapy are minimal, and consist mostly 
of temporary skin discoloration.56 Treatment 
after gynecomastia has developed is more prob-
lematic. After several months, glandular prolif-
eration, stromal expansion and periductal edema 
(the cause of initial discomfort) are replaced by 
fibrosis. At this time discomfort is reduced, but the 
gynecomastia is irreversible. Radiation therapy at 
this stage has minimal impact on breast size. It is 
important to note that gynecomastia also occurs 
in those treated by other hormonal modalities, 
especially NSAAs; increased circulating testo-
sterone induced by NSAA therapy is converted to 
estrogens within the peripheral adipose tissues.57 
Prophylactic radiotherapy or adjuvant tamoxifen 
is now commonly employed alongside NSAA 
therapy to reduce gynecomastia,58 and could be 
equally applied to parenteral estrogen therapy.
Parenteral estrogen therapy 
and the andropause
The abrupt suppression of androgens in men 
treated by current endocrine therapies results 
in a male version of the ‘climacteric’ similar to 
that experienced by women during menopause, 
sometimes termed andropause or castration 
syndrome. The best-recognized sequelae are loss 
of libido and erectile dysfunction. While sexual 
function in younger patients is intimately related 
to testosterone levels, in the elderly, mental and 
psychological factors are more important. Thus, 
the distress caused in these groups may be quite 
different. Castration syndrome also causes 
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Figure 4 Changes in bone mineral density in men 
treated with transdermal estradiol patches over 
1 year. (A) Changes in bone mineral density in the 
lumbar spine and (B) in total hip. Bars represent the 
mean and standard error of the mean. Permission 
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cognitive dysfunction, and complex psycho-
logical changes often associated with depression. 
These symptoms may be far more important to 
patients (and their relationships) than the sexual 
changes or hot flashes commonly emphasized in 
counseling by urologists. 
Evidence to demonstrate the deleterious effect 
of andropause on patients’ QOL is now accu-
mulating. While patients with symptomatic 
meta stases generally show improvement or 
stabilization of QOL parameters with short-
term (i.e. up to 1 year) endocrine therapy,59,60 
patients with non-symptomatic metastastic 
disease are adversely affected by androgen 
suppression. Decreases in physical, cognitive 
and emotional function as well as fatigue, leth-
argy and depression, have been widely recog-
nized.9,61,62 These adverse effects are most 
marked with LHRH agonists, especially when 
combined with an NSAA as MAB.63,64 For those 
with early-stage disease committed to long-term 
therapy the detrimental effects are even more 
apparent. The progressive deterioration in QOL 
scores is independent of the disease status, and 
worsens over time.10 
In these aspects, parenteral estrogen therapy 
might have significant advantages over other 
endocrine therapies. Epidemiological and experi-
mental data suggest that estrogen therapy may 
protect against age-related decline in cognitive 
function and dementia.14 Our own data seem 
to support this hypothesis at least in the shorter 
term. Patients treated with transdermal estradiol 
had an improved overall QOL during the first 
year of therapy, because of stabilized or improved 
functional and emotional status, reduced disease-
related symptoms and minimal andropause 
scores.65 The scores compared favorably with 
those expected from the reference population 
(Figure 5). This benefit is accrued whether the 
patients presented with symptomatic or asymp-
tomatic disease. It is not yet clear whether the 
apparent benefits of transdermal estradiol 
therapy continue with longer duration therapy.
ECONOMIC BENEFITS OF PARENTERAL 
ESTROGEN THERAPY
The rising cost of endocrine therapy for CaP has 
been an issue of increasing concern amongst 
health-care providers throughout the world. 
In the US, Medicare expenditure on LHRH 
agonists increased from US$477 million in 1994 
to over $800 million in 1999, and approaches 
$2 billion annually worldwide.66,67 Analysis of 
cost- effectiveness and quality-adjusted life years 
(QALY) is now a topic of serious debate. A cost:
QALY ratio of less than $20,000/QALY is univer-
sally considered to represent a reasonable use of 
health-care resource (i.e. good value). In a meta-
analysis,66 the historical use of oral estrogens 
was compared to current endocrine therapy by 
orchiectomy, LHRH agonists, NSAAs and MAB. 
The cardiovascular toxicity of oral estrogens was 
adjusted for within the analysis. The analysis 
demonstrated a QALY of 4.64 for oral estrogen 
therapy, 5.03 for NSAAs, 5.03 for MAB, and 5.10 
for LHRH agonists and orchiectomy. This small 
QALY benefit of current therapies over oral 
estrogens (i.e. a maximum improvement of 0.46 
QALY) was achieved at an astounding cost. Oral 
estrogens cost $8,100/QALY less than orchiec-
tomy, whilst LHRH agonists or NSAAs cost over 
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quality of life during 12 months of transdermal 
estradiol therapy as measured by EORTC QLQ-
C30 and PR25 CaP-specific QOL questionnaires. 
The vertical lines represent means and 95% 
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$100,000/QALY, and MAB $1,110,000/QALY, 
more than orchiectomy.66
Transdermal estradiol monotherapy costs 
approximately one-tenth the price of LHRH 
agonist therapy alone, and the disparity increases 
further when compared with LHRH and NSAA 
combination therapy and/or bisphosphonates. A 
crude estimate of the cost saving for endocrine 
therapy alone would amount to approximately 
£100,000,000 in the UK and $900,000,000 in 
the US each year.68 A substantial disparity 
remains even once the possibility of reduced 
LHRH agonist cost following patent expira-
tion is considered. Additional savings accrue 
if the potential of parenteral estradiol therapy 
to confer long-term cardioprotective and 
osteo porotic benefit is also considered. Even if 
estrogen therapy resulted in a small reduction 
in the incidence of these complications, the cost 
savings would be considerable. 
CONCLUSIONS AND FUTURE DIRECTIONS
The recognition of oral estrogen toxicity and 
the introduction of new hormone therapies 
led to the rapid demise of estrogen use in CaP. 
The mechanisms of toxicity and the potential to 
circumnavigate these problems were given scant 
regard, and the benefits of an estrogenic milieu 
received little consideration. The morbidity 
of contemporary hormone therapies has only 
recently been addressed, and the established 
health industry has embraced this new aware-
ness by promoting adjuvant therapies to protect 
against osteoporosis and andropause, but sees 
little incentive in developing old treatments. 
With the new and expanding indications for 
androgen deprivation, the long-term toxicities 
of current hormone therapies are no longer 
acceptable. As such, it is incumbent upon clini-
cians and health economies to re-evaluate the 
old and validate the new data presented. 
The future of estrogen in the management 
of CaP remains contemporary, evolving and 
exciting. Parenteral estrogen delivery may offer 
the benefits of oral estrogens with a substantially 
reduced cardiovascular risk. With parenteral 
delivery, this risk seems to be equivalent to that 
associated with orchiectomy, LHRH agonists 
and NSAAs for patients with metastatic disease. 
For patients with locally-advanced disease the 
risk may be more than with current therapies, 
but substantially lower than that of oral estro-
gens used historically. Over the longer term, 
this increase in cardiovascular morbidity could 
be converted into a substantial cardiovascular 
benefit. As such, clinicians and patients might 
choose to accept an initially higher risk in 
exchange for protection against osteoporosis, 
andropause and a better QOL. 
Transdermal patches are easy to apply, dose 
modulate, and withdraw in the advent of toxicity 
developing. The development of selective 
estrogen (and androgen) receptor modulators 
might provide targeted hormonal benefits in the 
future, and the opportunities for translational 
research appear considerable. Parenteral estro-
gens should be considered as first-line therapy, a 
second-line treatment (to reduce the toxicity of 
oral estrogens) of locally advanced and metastatic 
CaP, an alternative adjuvant to radiotherapy, and 
a high-dose treatment for men with androgen-
independent disease, as part of the multimodal 
armamentarium available to clinicians.
A phase II randomized controlled trial of 
transdermal estradiol compared with LHRH 
agonists began recruitment in April 2006 in 
collaboration with the Clinical Trials Unit of 
the Medical Research Council supported by the 
National Cancer Research Network Prostate 
Cancer UK studies group and funded by Cancer 
Research UK. The prospects of a new estrogen 
dawn look promising.
KEY POINTS
■ Oral estrogens were abandoned as first-line 
hormone therapy for CaP because of their 
cardiovascular and thromboembolic toxicity
■ Thromboembolic toxicity during first pass 
absorption of estrogens from the gut necessitates 
the need for parenteral routes of administration, 
which reduce thromboembolic risk
■ Cardiovascular toxicity is related to estrogen-
mediated vascular effects, which are both 
dose-dependent and time-dependent. Whilst 
short-term estrogen therapy has an increased 
risk of cardiovascular toxicity, long-term 
estrogen therapy may be associated with a 
cardiovascular benefit 
■ Current conventional androgen deprivation 
therapy is associated with considerable 
morbidity (castration syndrome/andropause) 
resulting in osteoporosis, hot flashes, cognitive 
dysfunction, asthenia and anemia
■ Estrogen therapy is protective against the 
andropausal side effects of current hormone 
therapies
■ Estrogen therapy is cheap with substantial 
health-care economic implications
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